Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Stage/Subtype:  recurrent malignant mesothelioma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-17 of 17 for your search:
Start Over
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0905, NCI-2011-02015, CDR0000665415, SWOG-S0905, NCT01064648
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TL139204, NCI-2015-00076, NCT00685204
Pentostatin, Cyclophosphamide, and SS1(dsFv)-PE38 Immunotoxin in Treating Patients with Mesothelioma, Lung Cancer, or Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0160, NCI-2013-01490, 110160, P10761, 8980, NCT01362790
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: VS-6063-202, NCI-2013-01412, NCT01870609
Pembrolizumab in Treating Patients with Malignant Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-1381, NCI-2015-00348, NCT02399371
Viral Therapy in Treating Patients with Primary, Metastatic, or Mesothelioma-Related Malignant Pleural Effusion
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-169, NCI-2013-00105, GL-ONC1-003/MSKCC, MSKCC-12169, NCT01766739
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00789, NCT02414269
Vaccine Therapy and Celecoxib in Treating Patients with Lung Cancer, Esophageal Cancer, Thymic Cancers, Thoracic Sarcomas, or Malignant Pleural Mesotheliomas Undergoing Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0041, NCI-2013-01472, 110041, P09574, NCT01258868
Amatuximab in Treating Patients with Advanced Pancreatic, Mesothelioma, Ovarian, or Non-Small Cell Lung Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0212, NCI-2013-01497, 009-006, 110212, P10769, NCT01413451
Proton Beam Radiation Therapy in Treating Patients with Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Phase: No phase specified
Type: Treatment
Age: 19 and older
Trial IDs: 9148, NCI-2014-01468, NCT02204761
Start Over